Dr. Giralt on Allogeneic HCT in Multiple Myeloma
Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.
Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, the Melvin Berlin Family Chair in Multiple Myeloma, and chief attending of adult bone marrow transplant service at Memorial Sloan Kettering Cancer Center, discusses the role of allogeneic hematopoietic cell therapy (HCT) in patients with multiple myeloma.
Giralt says this is a valid option for patients and should not be dismissed. This option has been available to patients for over 2 decades, though experts are aware that the results aren’t exactly what they hope. A number of clinical trials are exploring allogeneic HCT to improve the outcomes for these patients.
In particular, allogenic HCT provides a chance for long-term disease control in younger patients who have experienced multiple relapses.
